DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates
DENVER , May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita: International Expansion And Buybacks Will Boost Returns
International expansion continues with new clinics in Brazil, Ecuador, Chile, and Colombia, supporting long-term growth beyond the US market. DaVita's stock offers a 10% FCF yield, and the share count is decreasing at a fast pace. On top of share buybacks, the company will grow revenues above inflation due to its defensive business model and 35% market share.
DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship
Captures key initiatives achieved in 2024, driving 2025 ESG goals DENVER , May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its Community Care report, underpinning its long-standing commitment to corporate citizenship and highlighting strides made towards ambitious Environmental, Social and Governance (ESG) goals set to be achieved this year. Milestones and achievements reflect calendar year 2024.
DaVita Inc. Announces Offering of $750 Million Senior Notes
DENVER , May 20, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today that it has commenced a private offering (the "offering") of $750 million aggregate principal amount of its senior notes due 2033 (the "2033 notes"), subject to market and other conditions. DaVita intends to use the net proceeds from the offering (i) to repay outstanding revolving credit facility borrowings, together with related accrued and unpaid interest thereon, (ii) to pay any costs, fees and expenses in connection with the foregoing, and (iii) if any proceeds remain, for general corporate purposes, including, without limitation, for repurchases of capital stock, working capital and capital expenditures.
Here's Why DaVita HealthCare (DVA) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract
Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.
DaVita Inc. (DVA) Q1 2025 Earnings Call Transcript
DaVita Inc. (NYSE:DVA ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Nic Eliason - Group VP, IR Javier Rodriguez - CEO Joel Ackerman - CFO Conference Call Participants Andrew Mok - Barclays Christian Porter - Bank of America Dean Rosales - Wolfe Research Pito Chickering - Deutsche Bank A.J. Rice - UBS Ryan Langston - TD Cowen Operator Good evening.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
DaVita HealthCare (DVA) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $2.38 per share a year ago.
DaVita First-Quarter 2025 Financial Results: Just the Numbers
Kidney treatment company DaVita (DVA) on Monday afternoon reported first-quarter 2025 financial results. A summary of its key numbers is below.
DaVita Inc. 1st Quarter 2025 Results
DENVER , May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders.
